Adial Pharmaceuticals Inc trades as part of the biotechnology industry and is in the healthcare sector. The company CEO is William B. Stilley. Adial Pharmaceuticals Inc is a United States-based pharmaceutical company. The company develops prescription medications for addiction and related disorders.
Previous Intraday Performance:
The ADIL shares had a previous change of -0.87% which opened at 2.29 and closed at 2.28. It moved to an intraday high of 2.31 and a low of 2.21.
SeekingAlpha: AIG, GWPH among premarket gainers
Historical Performance:
Over the last five trading days, ADIL shares returned 3.64% and in the past 30 trading days it returned -22.18%. Over three months, it changed -32.34%. In one year it has changed -43.70% and within that year its 52 week high was 9.44 and its 52 week low was 1.11. ADIL stock is 106.24% above its 52 week low.
Our calculations result in a 200 day moving average of 3.37 and a 50 day moving average of 2.75. Right now, ADIL stock is trading -32.39% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.
SeekingAlpha: AIG, GWPH among premarket gainers
Liquidity:
The company has a market cap of $23.3m with 10.2m shares outstanding and a float of 8.9m shares. Trading volume was 12,590 shares and has experienced an average volume of 102,602 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.
Earnings:
The last annual reported EPS for Adial Pharmaceuticals Inc was -1.81 which ended on 31st of December 2018. Based on 1 analyst estimate, the estimated EPS for the next quarter is 0.00.
Below was the last reported quarterly diluted earnings per share:
| 1st | Qtr 2019 | -0.33 |
|---|---|---|
| 4th | Qtr 2018 | 0.07 |
| 3rd | Qtr 2018 | -1.48 |
| 2nd | Qtr 2018 | -0.33 |
| 1st | Qtr 2018 | -0.07 |
The long-term trend of the EPS is an important number as it indicates the present value of Adial Pharmaceuticals Inc.
Indicators Also to Watch:
Based on the latest filings, there is 19.80% of insider ownership and 5.60% of institutional ownership.
The beta was calculated to be -0.33.
SeekingAlpha: Advanced Emissions Solutions Inc. (ADES) CEO Heath Sampson on Q1 2019 Results – Earnings Call Transcript
Fundamental Numbers:
Based on last reported financials, the company’s return on equity is -267.38%, return on assets is -229.57% and price-to-book is 1.99.
Company Score Card:
Results are out of six:
3 : Growth Expectations Result
6 : Financial Safety Result
0 : Past Performance Result
1 : Valuation Result
0 : Dividend Safety Result
2 : Overall Result
Related Tags: Adial Pharmaceuticals Inc, ADIL, Biotechnology, Healthcare
